STOCK TITAN

[Form 4] Avita Medical, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.

David O'Toole, identificato come Chief Financial Officer, ha depositato un Form 4 che segnala una variazione della titolarità effettiva di Avita Medical, Inc. (RCEL). Il documento indica l'acquisto di 2,000 azioni ordinarie in data 08/12/2025 al prezzo di $4.81 per azione, portando la sua partecipazione diretta a 29,657 azioni. L'operazione è segnalata con il codice di transazione P e il Form 4 è stato presentato da una sola persona dichiarante.

David O'Toole, identificado como Chief Financial Officer, presentó un Form 4 informando un cambio en la titularidad de Avita Medical, Inc. (RCEL). El informe muestra que adquirió 2,000 acciones ordinarias el 08/12/2025 a un precio de $4.81 por acción, incrementando su tenencia directa a 29,657 acciones. La transacción se reporta con el código P y el Form 4 fue presentado por una sola persona informante.

David O'Toole은 최고재무책임자(CFO)로 확인되며, Avita Medical, Inc. (RCEL)에 대한 실질 소유권 변동을 보고하는 Form 4를 제출했습니다. 서류에 따르면 그는 08/12/2025에 보통주 2,000주를 주당 $4.81에 취득하여 그의 직접 보유량이 29,657주로 증가했습니다. 거래는 거래 코드 P로 보고되었고, Form 4는 한 명의 보고인이 제출했습니다.

David O'Toole, identifié comme Chief Financial Officer, a déposé un Form 4 signalant un changement de détention bénéficiaire de Avita Medical, Inc. (RCEL). Le dépôt indique qu'il a acquis 2,000 actions ordinaires le 08/12/2025 au prix de $4.81 par action, portant sa détention directe à 29,657 actions. La transaction est déclarée sous le code P et le Form 4 a été déposé par une seule personne déclarante.

David O'Toole, ausgewiesen als Chief Financial Officer, hat ein Form 4 eingereicht, das eine Änderung des wirtschaftlichen Eigentums an Avita Medical, Inc. (RCEL) meldet. Dem Eintrag zufolge erwarb er am 08/12/2025 2,000 Stammaktien zu je $4.81, wodurch seine direkten Bestände auf 29,657 Aktien stiegen. Die Transaktion ist mit dem Transaktionscode P gemeldet, und das Form 4 wurde von einer meldenden Person eingereicht.

Positive
  • Reported acquisition: David O'Toole purchased 2,000 shares at $4.81, increasing direct holdings to 29,657.
  • Clear disclosure: Form 4 identifies the reporting person as CFO and was filed by one reporting person, with transaction date 08/12/2025.
Negative
  • None.

Insights

TL;DR: Officer purchased a modest block of shares; the immediate market impact is likely limited.

The Form 4 documents a purchase of 2,000 shares at $4.81, raising direct holdings to 29,657 shares. For a public company, this size of purchase by a named officer is a straightforward insider acquisition disclosure. There are no derivative transactions or disposals reported. Based solely on the filing, the transaction appears routine and not material to company capital structure.

TL;DR: Disclosure appears complete and timely for a single reporting officer.

The Form 4 names the reporting person, relationship (CFO), transaction date (08/12/2025), transaction code (P), number of shares acquired (2,000) and resulting direct ownership (29,657). The form indicates a single filer and shows no amendments. From a compliance perspective, the filing meets standard Section 16 disclosure elements contained in the document.

David O'Toole, identificato come Chief Financial Officer, ha depositato un Form 4 che segnala una variazione della titolarità effettiva di Avita Medical, Inc. (RCEL). Il documento indica l'acquisto di 2,000 azioni ordinarie in data 08/12/2025 al prezzo di $4.81 per azione, portando la sua partecipazione diretta a 29,657 azioni. L'operazione è segnalata con il codice di transazione P e il Form 4 è stato presentato da una sola persona dichiarante.

David O'Toole, identificado como Chief Financial Officer, presentó un Form 4 informando un cambio en la titularidad de Avita Medical, Inc. (RCEL). El informe muestra que adquirió 2,000 acciones ordinarias el 08/12/2025 a un precio de $4.81 por acción, incrementando su tenencia directa a 29,657 acciones. La transacción se reporta con el código P y el Form 4 fue presentado por una sola persona informante.

David O'Toole은 최고재무책임자(CFO)로 확인되며, Avita Medical, Inc. (RCEL)에 대한 실질 소유권 변동을 보고하는 Form 4를 제출했습니다. 서류에 따르면 그는 08/12/2025에 보통주 2,000주를 주당 $4.81에 취득하여 그의 직접 보유량이 29,657주로 증가했습니다. 거래는 거래 코드 P로 보고되었고, Form 4는 한 명의 보고인이 제출했습니다.

David O'Toole, identifié comme Chief Financial Officer, a déposé un Form 4 signalant un changement de détention bénéficiaire de Avita Medical, Inc. (RCEL). Le dépôt indique qu'il a acquis 2,000 actions ordinaires le 08/12/2025 au prix de $4.81 par action, portant sa détention directe à 29,657 actions. La transaction est déclarée sous le code P et le Form 4 a été déposé par une seule personne déclarante.

David O'Toole, ausgewiesen als Chief Financial Officer, hat ein Form 4 eingereicht, das eine Änderung des wirtschaftlichen Eigentums an Avita Medical, Inc. (RCEL) meldet. Dem Eintrag zufolge erwarb er am 08/12/2025 2,000 Stammaktien zu je $4.81, wodurch seine direkten Bestände auf 29,657 Aktien stiegen. Die Transaktion ist mit dem Transaktionscode P gemeldet, und das Form 4 wurde von einer meldenden Person eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Toole David D

(Last) (First) (Middle)
28159 AVENUE STANFORD
SUITE 220 - AVITA MEDICAL

(Street)
VALENCIA CA 91355

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/12/2025 P 2,000 A $4.81 29,657 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
David O'Toole 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Avita Medical (RCEL)?

David O'Toole, identified as the Chief Financial Officer, filed the Form 4.

What transaction is reported in the RCEL Form 4 dated 08/12/2025?

The filing reports the acquisition of 2,000 common shares on 08/12/2025 at a price of $4.81 per share, transaction code P.

How many Avita Medical (RCEL) shares does David O'Toole own after the reported transaction?

Following the reported transaction, his direct beneficial ownership is 29,657 shares.

Was the Form 4 filed jointly or by a single reporting person?

The Form 4 indicates it was filed by one reporting person.

Does the filing report any derivative securities or option transactions?

No. Table II for derivative securities contains no entries in this filing.
Avita Medical Inc

NASDAQ:RCEL

RCEL Rankings

RCEL Latest News

RCEL Latest SEC Filings

RCEL Stock Data

127.15M
26.22M
0.83%
26.37%
21.58%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
VALENCIA